The Developmental Research Program (DRP) of the University of Texas SPORE in Lung Cancer is an integral part of the overall Lung Cancer SPORE research. This Program provides, after selection by external review and applicant discussion with senior SPORE investigators, a flexible and nimble platform for seed funding of novel research that have potential to significantly impact lung cancer translational research. It is designed to fund promising early stage projects that address important translational objectives in early detection, prevention, and therapy of lung cancer. Through institutional commitments at both UTSW and UTMDACC there are $300,000 in funds (that can be used for DRP or CDP Projects) matched to the $50,000 DRP funds provided by the grant. The DRP program has evolved into a highly structured process for solicitation, evaluation and collaboration with skilled scientists inside and outside UTSW and UTMDACC institutions. We want to attract new investigators to lung cancer translational research who have novel approaches and techniques that address significant barriers in lung cancer and which could benefit from SPORE Core Resources, interaction and mentorship, and that have potential to synergize with our existing Projects. The DRP has resulted in a large number of publications, new lung cancer translational scientists, and new peer reviewed grants. We have the following Specific Aims: 1. Provide Development Project funding to projects focused on lung cancer translational research. 2. Use the expertise of UTSW and MDACC scientific and clinical leaders and SPORE investigators and Core leaders to identify high impact lung cancer translational projects in the UTSW, UTMDACC and related environments. 3. Build on well-established SPORE mechanisms for mentorship of and integration with SPORE investigators, Projects, and Cores. 4. Build on the existing SPORE framework to promote communication between basic and clinical scientists, within and outside UTSW and UTMADCC, across disciplines, and guide the training of a new generation of translational researchers. 5. Facilitate development and transition of these successful projects into competitive applications for peer-reviewed funding. 6. Build on existing SPORE mechanisms to translate the findings into the clinic.

Public Health Relevance

Over the last 20 years, the 5-year survival rate for lung cancer has improved only by 2%, from 13 percent to 15 percent. That statistics alone is an urgent call for accelerated translational lung cancer research. The primary objective of the DRP is to provide a source of seed funding to 1) support innovative and meritorious Lung (Dancer projects within and outside UTSW and UTMDACC; 2) establish functional collaborative networks; and 3) recruit highly qualified new investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-20
Application #
9552722
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Shidan; Chen, Alyssa; Yang, Lin et al. (2018) Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8:10393
Gomez, Daniel Richard; Byers, Lauren Averett; Nilsson, Monique et al. (2018) Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9:14268-14284
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93
Yamauchi, Mitsuo; Barker, Thomas H; Gibbons, Don L et al. (2018) The fibrotic tumor stroma. J Clin Invest 128:16-25
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Yi, Faliu; Yang, Lin; Wang, Shidan et al. (2018) Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks. BMC Bioinformatics 19:64
Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48

Showing the most recent 10 out of 1059 publications